Ocata Therapeutics (Ocata Therapeutics) Cash Receipts from Securities Related Activities

Ocata Therapeutics Inc was incorporated in Nevada under the name Two Moon Kachinas Corp. on May 18, 2000. The Company is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. It has developed a human photoreceptor progenitor cell. In the U.S., one of the Company's ongoing clinical trials is a Phase 1/2 study for treating dry AMD patients by injection of RPE cells made in culture from an hESC line. It is also conducting Phase 1/2 studies in both the U.S. and the U.K. for the treatment of SMD patients using the RPE cell injections. The Company is conducting three trials in cooperation with retinal surgeons at the top eye hospitals in the U.S. and the U.K. including: Jules Stein Eye Institute (UCLA), Wills Eye Institute, Bascom Palmer Eye Institute (University of Miami) and Massachusetts Eye and Ear Infirmary. As of March 27, 2014, the Company had 46 issued patents and 178 pending patent applications filed, a substantial portion of which pertain to its active product development programs. The Company competes with Pfizer, Regenerative Patch Technologies and the Riken Center for Developmental Biology (Japan), among others. The Company's research and development activities are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.